Top View
- The Microtubule-Stabilizing Agents Epothilones a and B and Their Desoxy-Derivatives Induce Mitotic Arrest and Apoptosis in Human Prostate Cancer Cells
- Centre for Reviews and Dissemination Topotecan, Pegylated Liposomal
- Pharmacokinetically Guided Phase I Trial of Topotecan and Etoposide Phosphate in Recurrent Ovarian Cancer
- Phase II Study of Topotecan and Etoposide As Second-Line Treatment in Chemotherapy-Refractory Small-Cell Lung Cancer
- Systemic MEK Inhibition Enhances the Efficacy of 5-Aminolevulinic Acid
- Topotecan and Doxorubicin Combination to Treat Recurrent
- 29, 37 Acantholytic Carcinoma, 141 Ac1arubicin, 214 Acquired
- DRUG NAME: Topotecan
- 2019 Table of Drugs
- Topotecan and Doxorubicin Combination to Treat Recurrent
- Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic
- Identification of Cisplatin Sensitizers Through High-Throughput Combinatorial Screening
- Hycamtin, INN-Topotecan
- Full Prescribing Information for TOPOTECAN INJECTION
- New Trends for Overcoming ABCG2/BCRP-Mediated Resistance
- Emetogenic Potential of Antineoplastic Agents
- HYCAMTIN 4 (Topotecan Hydrochloride) 5 for Injection 6 for INTRAVENOUS USE
- A New Multidrug Reinduction Protocol with Topotecan, Vinorelbine
- HYCAMTIN Injection
- Cisplatin and Thoracic Irradiation in Patients with Limited Small Cell Lung Cancer1
- Topotecan Hydrochloride (Hycamtin)
- Oxaliplatin Plus Leucovorin and 5-Fluorouracil (FOLFOX-4)
- Irinotecan, Topotecan, Paclitaxel Or Docetaxel for Second-Line Treatment of Small Cell Lung Cancer
- Sequencing Topotecan and Etoposide Plus Cisplatin to Overcome Topoisomerase I and II Resistance: a Pharmacodynamically Based Phase I Trial
- Phase II Trial of High-Dose Topotecan, Melphalan and CY with Autologous Stem Cell Support for Multiple Myeloma
- (Arsenic Trioxide) in the Treatment of Myelodysplastic Syndromes
- Advances in the Systemic Treatment of Leptomeningeal Cancer Taher Abu Hejleh, MBBS, and Gerald Clamon, MD
- Arsenic Trioxide Reverses the Chemoresistance in Hepatocellular Carcinoma
- Novel Therapies for Relapsed and Refractory Neuroblastoma
- Cisplatin & Topotecan for Cervical Cancer
- BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- A Randomized Trial to Compare Busulfan + Melphalan 140 Mg/M2
- Sequential Treatment with SN-38 Followed by 5-Fluorouracil Shows Synergistic Cytotoxic Activity in Small Cell Lung Cancer Cells
- ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy Marie Morfouace1, Satish Cheepala2, Sadhana Jackson1, Yu Fukuda2, Yogesh T
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Investigation of the Effect of IRAK1/4 Inhibitor on the Expression of P53
- Gynaecological Cancer
- Hycamtin, INN-Topotecan
- Hazardous Drug List
- Hycamtin, INN-Topotecan
- Phase I Trial of Sequential Topotecan Followed by Etoposide in Adults With
- BC CANCER CHEMOTHERAPY PREPARATION and STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative
- Topotecan, Thiotepa, and Carboplatin for Neuroblastoma: Failure to Prevent Relapse in the Central Nervous System